Sofosbuvir
Chronic Hepatitis C
Peking University First HospitalSmall moleculePhase 4 / ApprovedDormant
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 71/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Chronic Hepatitis C cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ribavirin Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | Phase 4 | A |
PARITAPREVIR Ain Shams University | Phase 3 | A |
Dasabuvir AbbVie | Phase 3 | A |
OMBITASVIR Ain Shams University | Phase 3 | A |
Pegylated Interferon Alpha2A Hoffmann-La Roche | Phase 4 | A |
View all 50 →
Same molecule, other indications
Sofosbuvir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →